OFFICIAL



NHS Framework Agreement for the Supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

Offer reference number: CM/PHS/15/5500

Period of framework agreement: 1st July 2018 to 30th June 2019 with options to extend up to a further 36 months. Total maximum framework agreement including extension options will be no more than 48 months.

Post code of registered address for each awarded supplier together with SME indicator

Awarded supplier name	Post code of registered address	SME
CSL Behring UK Ltd	RH16 1AH	No
Pharming Group NV	NN4 7BZ	Yes
Shire Pharmaceuticals Ltd	W2 6BD	No